BCL2 and acute myeloid leukemia: Moreover, AML cell clones harboring mutant NRAS arise in some patients relapsing on targeted therapies, particularly FLT3 inhibition (crenolanib56 and gilteritinib57) and BCL2 inhibition in some cases (venetoclax58,59).